Merck KGaA Agrees to Acquire Bio-Techne for $11.3 Billion (merckgroup.com)

• Merck KGaA agrees to buy Bio-Techne for $11.3B in cash, a 36% premium.
• Bio-Techne adds multi-omics, protein analysis, and cell therapy tools to Merck's Life Science portfolio.
• Merck forecasts €140M annual cost synergies by year three; deal expected to close by early 2027.

"Merck KGaA has agreed to acquire Bio-Techne, a US-based life sciences tools company, for $73 per share in cash, implying an enterprise value of $11.3 billion. The deal is expected to close by late 2026 or early 2027. Merck will fund the acquisition with cash and debt, retaining an investment-grade rating. Bio-Techne's portfolio includes multi-omics, protein analysis, and cell therapy tools. Merck forecasts annual cost synergies of approximately €140 million by year three post-closing."